Matthieu Dietz, Vincent Dunet, Styliani Mantziari, Anastasia Pomoni, Ricardo Dias Correia, Nathalie Testart Dardel, Sarah Boughdad, Marie Nicod Lalonde, Giorgio Treglia, Markus Schafer, Niklaus Schaefer, John O Prior
{"title":"68Ga-NODAGA-RGD PET/CT检测整合素αvβ3表达及18F-FDG PET/CT检测食管癌和胃食管癌糖代谢的比较","authors":"Matthieu Dietz, Vincent Dunet, Styliani Mantziari, Anastasia Pomoni, Ricardo Dias Correia, Nathalie Testart Dardel, Sarah Boughdad, Marie Nicod Lalonde, Giorgio Treglia, Markus Schafer, Niklaus Schaefer, John O Prior","doi":"10.1186/s41824-023-00162-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The primary aims of this study were to compare in patients with esophageal or esophagogastric junction cancers the potential of <sup>68</sup>Ga-NODAGA-RGD PET/CT with that of <sup>18</sup>F-FDG PET/CT regarding tumoral uptake and distribution, as well as histopathologic examination.</p><p><strong>Methods: </strong>Ten <sup>68</sup>Ga-NODAGA-RGD and ten <sup>18</sup>F-FDG PET/CT were performed in nine prospectively included participants (1 woman; aged 58 ± 8.4 y, range 40-69 y). Maximum SUV (SUV<sub>max</sub>) and metabolic tumor volumes (MTV) were calculated. The Mann-Whitney U test and Spearman correlation analysis (ρ) were used.</p><p><strong>Results: </strong><sup>68</sup>Ga-NODAGA-RGD PET/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites. <sup>18</sup>F-FDG PET/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUV<sub>max</sub> of <sup>18</sup>F-FDG was significantly higher than those of <sup>68</sup>Ga-NODAGA-RGD (4.9 [3.7-11.3] vs. 3.2 [2.6-4.2] g/mL, p = 0.014). Only one participant showed a higher SUV<sub>max</sub> in an osseous metastasis with <sup>68</sup>Ga-NODAGA-RGD as compared to <sup>18</sup>F-FDG (6.6 vs. 3.9 g/mL). Correlation analysis showed positive correlation between <sup>18</sup>F-FDG and <sup>68</sup>Ga-NODAGA-RGD PET parameters (ρ = 0.56, p = 0.012 for SUV<sub>max</sub>, ρ = 0.78, p < 0.001 for lesion-to-background ratios and ρ = 0.58, p = 0.024 for MTV). We observed that <sup>18</sup>F-FDG uptake was homogenous inside all the confirmed primary sites (n = 9). In contrast, <sup>68</sup>Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%).</p><p><strong>Conclusions: </strong>In conclusion, <sup>68</sup>Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to <sup>18</sup>F-FDG. However, the results suggest that PET imaging of integrin α<sub>v</sub>β<sub>3</sub> expression may provide complementary information and could aid in tumor diversity and delineation.</p><p><strong>Trial registration: </strong>Trial registration: NCT02666547. Registered January 28, 2016-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02666547 .</p>","PeriodicalId":36160,"journal":{"name":"European Journal of Hybrid Imaging","volume":"7 1","pages":"3"},"PeriodicalIF":1.7000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889587/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of integrin α<sub>v</sub>β<sub>3</sub> expression with <sup>68</sup>Ga-NODAGA-RGD PET/CT and glucose metabolism with <sup>18</sup>F-FDG PET/CT in esophageal or gastroesophageal junction cancers.\",\"authors\":\"Matthieu Dietz, Vincent Dunet, Styliani Mantziari, Anastasia Pomoni, Ricardo Dias Correia, Nathalie Testart Dardel, Sarah Boughdad, Marie Nicod Lalonde, Giorgio Treglia, Markus Schafer, Niklaus Schaefer, John O Prior\",\"doi\":\"10.1186/s41824-023-00162-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The primary aims of this study were to compare in patients with esophageal or esophagogastric junction cancers the potential of <sup>68</sup>Ga-NODAGA-RGD PET/CT with that of <sup>18</sup>F-FDG PET/CT regarding tumoral uptake and distribution, as well as histopathologic examination.</p><p><strong>Methods: </strong>Ten <sup>68</sup>Ga-NODAGA-RGD and ten <sup>18</sup>F-FDG PET/CT were performed in nine prospectively included participants (1 woman; aged 58 ± 8.4 y, range 40-69 y). Maximum SUV (SUV<sub>max</sub>) and metabolic tumor volumes (MTV) were calculated. The Mann-Whitney U test and Spearman correlation analysis (ρ) were used.</p><p><strong>Results: </strong><sup>68</sup>Ga-NODAGA-RGD PET/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites. <sup>18</sup>F-FDG PET/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUV<sub>max</sub> of <sup>18</sup>F-FDG was significantly higher than those of <sup>68</sup>Ga-NODAGA-RGD (4.9 [3.7-11.3] vs. 3.2 [2.6-4.2] g/mL, p = 0.014). Only one participant showed a higher SUV<sub>max</sub> in an osseous metastasis with <sup>68</sup>Ga-NODAGA-RGD as compared to <sup>18</sup>F-FDG (6.6 vs. 3.9 g/mL). Correlation analysis showed positive correlation between <sup>18</sup>F-FDG and <sup>68</sup>Ga-NODAGA-RGD PET parameters (ρ = 0.56, p = 0.012 for SUV<sub>max</sub>, ρ = 0.78, p < 0.001 for lesion-to-background ratios and ρ = 0.58, p = 0.024 for MTV). We observed that <sup>18</sup>F-FDG uptake was homogenous inside all the confirmed primary sites (n = 9). In contrast, <sup>68</sup>Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%).</p><p><strong>Conclusions: </strong>In conclusion, <sup>68</sup>Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to <sup>18</sup>F-FDG. However, the results suggest that PET imaging of integrin α<sub>v</sub>β<sub>3</sub> expression may provide complementary information and could aid in tumor diversity and delineation.</p><p><strong>Trial registration: </strong>Trial registration: NCT02666547. Registered January 28, 2016-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02666547 .</p>\",\"PeriodicalId\":36160,\"journal\":{\"name\":\"European Journal of Hybrid Imaging\",\"volume\":\"7 1\",\"pages\":\"3\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889587/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Hybrid Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41824-023-00162-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Hybrid Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41824-023-00162-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers.
Background: The primary aims of this study were to compare in patients with esophageal or esophagogastric junction cancers the potential of 68Ga-NODAGA-RGD PET/CT with that of 18F-FDG PET/CT regarding tumoral uptake and distribution, as well as histopathologic examination.
Methods: Ten 68Ga-NODAGA-RGD and ten 18F-FDG PET/CT were performed in nine prospectively included participants (1 woman; aged 58 ± 8.4 y, range 40-69 y). Maximum SUV (SUVmax) and metabolic tumor volumes (MTV) were calculated. The Mann-Whitney U test and Spearman correlation analysis (ρ) were used.
Results: 68Ga-NODAGA-RGD PET/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites. 18F-FDG PET/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUVmax of 18F-FDG was significantly higher than those of 68Ga-NODAGA-RGD (4.9 [3.7-11.3] vs. 3.2 [2.6-4.2] g/mL, p = 0.014). Only one participant showed a higher SUVmax in an osseous metastasis with 68Ga-NODAGA-RGD as compared to 18F-FDG (6.6 vs. 3.9 g/mL). Correlation analysis showed positive correlation between 18F-FDG and 68Ga-NODAGA-RGD PET parameters (ρ = 0.56, p = 0.012 for SUVmax, ρ = 0.78, p < 0.001 for lesion-to-background ratios and ρ = 0.58, p = 0.024 for MTV). We observed that 18F-FDG uptake was homogenous inside all the confirmed primary sites (n = 9). In contrast, 68Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%).
Conclusions: In conclusion, 68Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to 18F-FDG. However, the results suggest that PET imaging of integrin αvβ3 expression may provide complementary information and could aid in tumor diversity and delineation.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
